Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on CJC-1295 with DAC has been registered.
- 1 registered study in total.
- None are currently enrolling — this research has already happened.
What kind of research
- 1 study actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 120 people took part in those.
How far along it is
- None have reached phase 3 — the large, late-stage trials where a drug has to prove itself before regulators will approve it.
- None have published results in the medical literature yet, so the findings are not yet open to outside scrutiny.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 1 of 1 trial for CJC-1295 with DAC.
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
ConjuChem
Obesity · HIV Infections
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when CJC-1295 with DAC is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.